Jim Simons Zymeworks Inc. Transaction History

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$4.65 - $7.43 $268,663 - $429,283	57,777 New	57,777 $355,000
Q2 2022 Aug 12, 2022	SELL	$4.82 - $7.7 $2.64 Million - $4.22 Million	-547,900 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$6.0 - $16.98 $2.31 Million - $6.54 Million	385,300 Added 236.96%	547,900 $3.59 Million
Q4 2021 Feb 11, 2022	BUY	$15.19 - $29.33 $2.47 Million - $4.77 Million	162,600 New	162,600 $2.67 Million
Q2 2021 Aug 13, 2021	SELL	$26.5 - $38.23 $3.69 Million - $5.32 Million	-139,100 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$29.83 - $56.81 $3.75 Million - $7.14 Million	125,700 Added 938.06%	139,100 $4.39 Million
Q4 2020 Feb 10, 2021	SELL	$39.12 - $54.99 $7.11 Million - $9.99 Million	-181,734 Reduced 93.13%	13,400 $633,000
Q3 2020 Nov 13, 2020	SELL	$29.21 - $46.58 $15.9 Million - $25.3 Million	-544,000 Reduced 73.6%	195,134 $9.09 Million
Q2 2020 Aug 13, 2020	SELL	$33.67 - $40.0 $2.04 Million - $2.42 Million	-60,613 Reduced 7.58%	739,134 $26.7 Million
Q1 2020 May 14, 2020	BUY	$24.28 - $49.8 $6.51 Million - $13.4 Million	268,152 Added 50.44%	799,747 $28.4 Million
Q4 2019 Feb 13, 2020	BUY	$24.84 - $45.46 $3.88 Million - $7.1 Million	156,088 Added 41.57%	531,595 $24.2 Million
Q3 2019 Nov 13, 2019	BUY	$22.78 - $29.08 $959,197 - $1.22 Million	42,107 Added 12.63%	375,507 $9.31 Million
Q2 2019 Aug 12, 2019	BUY	$15.0 - $22.49 $1.16 Million - $1.73 Million	77,000 Added 30.03%	333,400 $7.34 Million
Q1 2019 May 14, 2019	SELL	$14.02 - $16.74 $250,958 - $299,646	-17,900 Reduced 6.53%	256,400 $4.16 Million
Q4 2018 Feb 13, 2019	BUY	$10.95 - $15.44 $3 Million - $4.24 Million	274,300 New	274,300 $4.03 Million

Others Institutions Holding ZYME

# of Institutions

Shares Held

296K

Call Options Held

Put Options Held

Strategic Wealth Advisors Group, LLC Sacramento, CA

296K
Shares

$4.33 Million
0.08% of portfolio

View Full List

About Zymeworks Inc.

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $901M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

More about ZYME

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account